ESTRO 2024 - Abstract Book

S1847

Clinical - Mixed sites, palliation

ESTRO 2024

Overall survival was measured from randomisation until death from any cause. Quality-of-Life Adjusted Survival (QAS) was computed by multiplying Kaplan Meier survival probabilities with the UK utility weights obtained from the QLU-C10D.

Preferred place of care was classified into distinct categories: home or with relatives; hospital care; living in care home, hospice or other locations.

Results:

A baseline physical functioning score of >50 was associated with a 28% reduction in the risk of death (HR: 0.72, 99% CI: 0.54-0.95, p=0.003). After adjusting for key baseline factors, every 10-point increase in physical functioning led to a 9% reduction in the risk of death (HR: 0.91, 99% CI: 0.87 to 0.96, p<0.001). An increased risk of death was associated with higher levels of fatigue (HR 1.35, 99% CI: 1.03-1.76 p=0.004), dyspnoea (HR 1.61, 99% CI: 1.24-2.08, p<0.001) and appetite loss; (HR 1.25, 99% CI: 0.99-1.59, p=0.014). There was no significant difference between treatment arms for the average HRQoL across time for any of the HRQoL measures. The mean 12-weeks QAS in the 8Gy/1f arm was 3.39 weeks (95%CI: 3.11 to 3.67) and in the 20Gy/5f arm was 3.65 weeks (95%CI: 3.36 to 3.94), a difference of -0.26 weeks (1.99 days) 95%CI: -0.66 to 0.14; p=0.2. Overall QAS in the two arms is shown in the figure.

No statistical difference between the arms was seen for the functioning scales, global health status or QLU-C10D.

Figure:

Quality adjusted survival after radiotherapy for MSCC in the two arms of the SCORAD trial